Cellect Biotechnology Ltd. (NASDAQ:APOP) investors are busy throwing a party today following the news that the stem cell developer has achieved a major milestone with the conclusion of a large study on the use ApoGraft™ on stem cells derived from fat tissues.
The significance of the findings opens ApoGraft™ to be used by a much wider array of companies and medical centers worldwide developing stem cell based products and treatments. Of special importance are the aesthetic and orthopedic indications where fat-derived stem cells are the main raw material.
Until this study, ApoGraft™ was used on blood cells (hematopoietic) and, in studies to date, has proven to be beneficial in stem cells selection of bone marrow (including for treatment of cancer and autoimmune diseases). The new study conducted with samples obtained via liposuction from over 20 adult patients has shown significant beneficial effect of the Apograft process on both the number and activity of the fat-derived stem cells.
The study was conducted in collaboration with the Plastic Surgery Department and Stem Cells Laboratory of the Tel-Aviv Medical Center (Ichilov Hospital). Fat-derived stem cells were treated according to Cellect protocols and have shown that ApoGraft™ led to both an expansion of cells and an improvement in their unique cell activity and attributes. The ability of those cells to create colonies and differentiate into bone was enhanced significantly after only a short incubation.
Cellect CEO Shai Yarkoni commented, “This breakthrough finding is increasing our addressable market by an order of magnitude. We can now actively seek strategic alliances for the commercialization of ApoGraft™” in aesthetic medicine as well as orthopedic indications.”
“Cellect has reached a significant milestone in showing that the ApoGraft™ technology can be applied to the harvesting of fat derived stem cells and therefore can be immediately applied to creating business alliances with the vast numbers of companies using fat-derived stem cells but unable to produce large batches under cost effective conditions. Together with the bone marrow program, the fat-derived stem cells cover most of the raw materials used by the industry. We intend to translate this breakthrough to more clinical programs and multiple licensing deals,” Yarkoni added.
Shares of Cellect Biotechnology reacted to the news, rising nearly 26% to $10.00. APOP has a 1-year high of $13.50 and a 1-year low of $2.30. The stock’s 50-day moving average is $8.16 and its 200-day moving average is $8.17.
On the ratings front, H.C. Wainwright analyst Ram Selvaraju assigned a Buy rating on APOP, with a price target of $14, in a report issued on September 25. The current price target implies an upside of 51% from current levels. According to TipRanks.com, Selvaraju has a yearly average loss of 9.0%, a 34% success rate, and is ranked #4648 out of 4703 analysts.
Cellect Biotechnology engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. It also develops innovative technology which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods.